ArticleScientific reports2026
Alterations in peripheral blood B cell subsets and their clinical significance in systemic lupus erythematosus.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Next-generation immune cell engagers for B cell depletion in autoimmune diseases.Nature reviews. Drug discovery · 2026Review
- Adjuvant Molecular Hydrogen Facilitates Immunosuppressant Tapering and Sustained Remission in Systemic Lupus Erythematosus: A Case Report.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Systemic lupus erythematosus (SLE) is characterized by B-cell dysregulation and autoantibody production. This study aimed to characterize the alterations in peripheral blood B-cell subsets across different states of SLE and to evaluate their diagnostic value and association with specific autoantibodies.A total of 84 participants were enrolled, comprising 64 SLE patients (including 20 newly diagnosed, 27 stable, and 17 with lupus nephritis) and 20 healthy controls (HCs). Peripheral blood B-cell subsets, including naïve B-cells, memory B-cells, and plasmablasts, were analyzed by flow cytometry. Their diagnostic performance was assessed using Receiver Operating Characteristic (ROC) curve analysis. Associations with anti-nuclear antibody (ANA), anti-dsDNA, and anti-Sm antibody status were also evaluated.Compared to HCs, SLE patients exhibited significant disturbances in B-cell homeostasis. The most consistent finding was a profound decrease in the absolute frequency of memory B cells across all patient groups (newly diagnosed, stable, and LN; all p < 0.001). Newly diagnosed patients showed a significant expansion of plasmablasts (p = 0.017), which was less pronounced in stable and LN groups. ROC analysis demonstrated that the absolute memory B-cell frequency (memory B%) had outstanding diagnostic performance for SLE (AUC = 0.905, 80% sensitivity, 80% specificity). Furthermore, higher anti-nuclear antibody (ANA) titers and anti-dsDNA positivity were significantly associated with a decreased absolute naïve B-cell count and an increased relative proportion of plasmablasts. Anti-Sm positivity was specifically linked to a higher plasmablast proportion (p = 0.006).Our findings highlight a marked disruption of peripheral B-cell subsets in SLE, particularly a persistent reduction in memory B cells and an expansion of plasmablasts in active disease. Memory B cells serve as an excellent diagnostic biomarker, while plasmablast expansion is closely associated with specific autoantibodies, underscoring the pivotal role of aberrant B-cell differentiation in SLE immunopathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.